Forget buy-to-let! I’d buy these 2 FTSE 100 stocks to retire early

I think these two FTSE 100 (INDEXFTSE:UKX) shares could offer improving growth outlooks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The outlook for the buy-to-let industry may be more positive following the general election. Fears surrounding a Jeremy Corbyn-led government and potential changes to taxation may mean that house prices make gains in the short run.

However, in the long run, the FTSE 100 could outperform buy-to-let investments. It appears to offer superior value for money, greater diversity and a range of stocks with sound growth strategies.

With that in mind, here are two FTSE 100 shares that could deliver impressive long-term total returns. They could help to bring your retirement date a step closer.

AstraZeneca

Recent updates from pharma stock AstraZeneca (LSE: AZN) have provided evidence of the scale of its turnaround. While in previous years it has struggled to generate top- and bottom-line growth, its sales and profitability are now growing at double-digit rates. This trend could continue over the medium term as the business benefits from the major investment it has made in its pipeline over recent years.

Risks facing UK investors may have subsided following the recent general election. However, global growth uncertainties remain in place. For example, political risk in the US and China may continue to be high in 2020, while tariffs could act as a drag on global GDP growth. Therefore, AstraZeneca’s defensive characteristics could help it to outperform many of its FTSE 100 peers. Its reduced dependency on the wider economy’s performance may mean that it becomes more popular among investors.

As such, now could be the right time to buy a slice of the company. Its improving financial performance and increasing favour among investors may mean that it outpaces house price growth in the long run.

Bunzl

One FTSE 100 share that is being negatively impacted by an uncertain global macroeconomic outlook is Bunzl (LSE: BNZL). The international distribution and services company recently released a trading update that showed the slowing sales trend from earlier in 2019 has continued.

For example, in its third quarter, the company reported a rise in sales at constant exchange rates of just 0.5%. When the impact of acquisitions is excluded, its sales declined by 1%.

Looking ahead, Bunzl has an active acquisition pipeline. It has already spent £100m on acquisitions this year, and is likely to continue to add new businesses to its portfolio over the medium term. They could catalyse its financial performance and help to offset an uncertain trading period for the business.

With a solid track record of growth that includes five continuous years of increasing earnings, Bunzl could offer long-term growth potential. Following its 12% share price decline in the last year, now could be the right time to buy a slice of it while it trades on a lower valuation. It may fail to recover significantly in the short run, but could offer turnaround potential in the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Grey cat peeking out from inside a cardboard box in a house
Investing Articles

Just released: April’s latest small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »